KLRK1 anticorps (AA 121-219)

N° du produit ABIN730078

Détail du produit anti-KLRK1 anticorps

Antigène: KLRK1 (Killer Cell Lectin-Like Receptor Subfamily K, Member 1 (KLRK1))

Épitope: AA 121-219

Reactivité: Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp KLRK1 est non-conjugé

Application: Western Blotting (WB), Flow Cytometry (FACS), ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Réactivité croisée: Souris

Homologie: Human,Rat

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from rat KLRK1

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
ELISA 1:500-1000
FCM 1:20-100
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Date de péremption: 12 months

Références pour anticorps anti-KLRK1 (ABIN730078)

Mozer-Lisewska, Mania, Kowala-Piaskowska, Kluk, Samara, Pauli, ?eromski: "Detection and significance of cytotoxic cell subsets in biopsies of HCV-infected human livers." dans: Archivum immunologiae et therapiae experimentalis, Vol. 62, Issue 2, pp. 153-60, (2014) (PubMed).

Onishi, Kiyota, Koya, Tanaka, Umebayashi, Katano, Morisaki: "Random migration contributes to cytotoxicity of activated CD8+ T-lymphocytes but not NK cells." dans: Anticancer research, Vol. 34, Issue 8, pp. 3947-56, (2014) (PubMed).

Ruck, Bittner, Gross, Breuer, Albrecht, Korr, Göbel, Pankratz, Henschel, Schwab, Staszewski, Prinz, Kuhlmann, Meuth, Wiendl: "CD4+NKG2D+ T cells exhibit enhanced migratory and encephalitogenic properties in neuroinflammation." dans: PLoS ONE, Vol. 8, Issue 11, pp. e81455, (2013) (PubMed).

Détails sur KLRK1

Antigène: KLRK1 (Killer Cell Lectin-Like Receptor Subfamily K, Member 1 (KLRK1))

Autre désignation: NKG2D (KLRK1 Produits)

Synonymes: anticorps KLRK1, anticorps NKG2D, anticorps CD314, anticorps D12S2489E, anticorps KLR, anticorps NKG2-D, anticorps D6H12S2489E, anticorps Nkg2d, anticorps Nkrp2, anticorps killer cell lectin like receptor K1, anticorps killer cell lectin-like receptor subfamily K, member 1, anticorps NKG2D protein, anticorps KLRK1, anticorps Klrk1, anticorps NKG2D

Sujet:

Synonyms: NKG2D, Nkrp2, NKG2-D type II integral membrane protein, Killer cell lectin-like receptor subfamily K member 1, NK cell receptor D, NK lectin-like receptor, NKLLR, NKG2-D-activating NK receptor, NKR-P2, CD314, Klrk1

Background: Function as an activating and costimulatory receptor involved in immunosurveillance upon binding to various cellular stress-inducible ligands displayed at the surface of autologous tumor cells and virus-infected cells. Provides both stimulatory and costimulatory innate immune responses on activated killer (NK) cells, leading to cytotoxic activity. Acts as a costimulatory receptor for T-cell receptor (TCR) in CD8(+) T-cell-mediated adaptive immune responses by amplifying T-cell activation. Stimulates perforin-mediated elimination of ligand-expressing tumor cells. Signaling involves calcium influx, culminating in the expression of TNF-alpha. Participates in NK cell-mediated bone marrow graft rejection. May play a regulatory role in differentiation and survival of NK cells. Binds to ligands belonging to various subfamilies of MHC class I-related glycoproteins.

ID gène: 24934

UniProt: O70215

Pathways: Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process